CGEM
Cullinan Therapeutics, Inc. · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth -9.1% ·
share flow -14.3% ·
net new positions -10.0%
· formula
Broad distribution: falling shares and fewer holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q1 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 1 | -1 | 10.21K | $157,847 | n/a | −1 |
| Q2 2026 | 77 | +7 | 28.05M | $510.52M | +11 | −4 |
| Q1 2026 | 73 | +7 | 24.59M | $348.81M | +10 | −3 |
| Q4 2025 | 65 | +1 | 21.69M | $224.52M | +1 | n/a |
| Q3 2025 | 17 | +1 | 15.39M | $91.26M | +1 | n/a |
| Q2 2025 | 13 | 0 | 14.48M | $109.06M | +1 | −1 |
| Q1 2025 | 10 | -1 | 7.69M | $58.25M | n/a | −1 |
| Q4 2024 | 11 | 0 | 8.98M | $109.41M | n/a | n/a |
| Q3 2024 | 10 | +1 | 6.86M | $114.80M | +1 | n/a |
| Q2 2024 | 9 | n/a | 7.12M | $124.19M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Citadel Advisors ✦ | 2.75M | +2.4% | $20.80M | 0.0% | ▲ Add | 4 | SEC ↗ ×2 |
| 2 | State Street Global Advisors ✦ (passive) | 1.75M | -17.5% | $13.27M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 3 | Geode Capital Management ✦ (passive) | 1.24M | +2.2% | $9.40M | 0.0% | ▲ Add | 4 | SEC ↗ ×2 |
| 4 | Millennium Management ✦ | 783.18K | -6.1% | $5.93M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 5 | Marshall Wace ✦ | 568.00K | -12.8% | $4.30M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 6 | Renaissance Technologies ✦ | 363.01K | +90.5% | $2.75M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 7 | Wellington Management ✦ | 161.06K | +21.1% | $1.22M | 0.0% | ▲ Add | 4 | SEC ↗ ×2 |
| 8 | T. Rowe Price ✦ | 31.72K | +7.5% | $241,000 | 0.0% | ▲ Add | 4 | SEC ↗ |
| 9 | D. E. Shaw & Co. ✦ | 31.49K | -35.6% | $238,410 | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 10 | Two Sigma Investments ✦ | 14.80K | -64.9% | $112,006 | 0.0% | ▼ Trim | 4 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| Adage Capital Partners | $12.55M | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 172 holders, 65.27M shares, $895.39M reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 8.00K sh · $172,560
Officer · 30.00K sh · $607,800
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology